Back

Pharma

Pharma Pricing & Market Access Strategies

  • 13th October 2020
  • Zoom flag Zoom
  • ONLINE

What are the critical challenges in optimizing product's market access strategy around the world? Join us and gain insights on the best strategies, practices, challenges, innovations, technologies, and concepts surrounding the Pharma Pricing & Market Access Strategies. The presenters will focus on the newest information available and cover a wide range of relevant subjects.

What are the current key trends in the pharma market? What is the role of new technologies in supporting data generation to accelerate access to medicines? Let’s learn about trends in pharma contracting or the COVID-19’s impact on access and usage of medicines.

Read more

About Pharma Pricing & Market Access Strategies Event

This Live Event will focus on the latest developments and innovations in Pharma Pricing & Market Access including market access trends, evidence-based pricing, pricing and payer strategies, rare diseases, and innovations in therapeutics.

Attendees will have the opportunity to learn from industry leaders like Axel Boehnke, Jolanda Koenders, Jack Noble, David Bower or Carmen Montoto. Ask questions and seek practical solutions to industry challenges and explore future developments in Pharma Pricing & Market Access.

Who Should Attend

CEOs / Presidents / MDs, CCOs/CMOs/CDOs, Chief Executives, Directors, Vice Presidents, Department Heads, Leaders and Managers specializing in:

  • Business Development
  • Sales
  • Market Access
  • Marketing Intelligence
  • Product Launch
  • Pricing Policy
  • Health Technology Assessment
  • Health Informatics
  • Value Strategy
  • Tendering
  • Marketing
  • Pricing
  • Medical Director
  • Drug Pricing
  • Health Economics
  • Product Reimbursement
  • Real World Evidence
  • Data Sciences
  • P&MA

REQUEST A BROCHURE

To request an agenda for this Summit, please complete the details below. We will send you the agenda via email.

KEY PRACTICAL LEARNING POINTS

  • Market access trends
  • Recent developments and processes
  • Reimbursement: contracting and landscape
  • Data-requirements / registries
  • Pharma contracting as a tool to get patient access
  • New technologies in supporting data generation to accelerate access to medicines
  • COVID-19’s impact on access and usage of medicines
  • HTA Bodies engagement to Identify Accelerated Access Opportunities

Axel Boehnke, DE

Director of Market Access EU North

PTC Therapeutics

Axel Boehnke is the Director Market Access EU North for PTC Therapeutics. He´s fully responsible for all market access aspects, P&R issues, accelerated patient access, early evidence planning, and institutional interactions, focusing on orphan diseases and Gene Therapy. Before, Axel was a Director Market Access at MorphoSys AG, focusing on oncology and especially r/r DLBCL. He has in-depth knowledge and expertise in the specialized business, like Oncology, Autoimmune Diseases, (Ultra) Orphan Diseases, Hepatology, Anti-virals, etc. He also has in track record experience in therapeutic mass markets like cardiovascular or osteoporosis, with respective payer-interactions and contracting. Axel started with Humira at Abbott in national responsibility, headed the Department of Market Access, managed Care at Servier, and served for experience in the biopharmaceutical industry for the last years. He is a Health Economist (University of Cologne) by education and holds a master’s degree in health and medical management (University Erlangen-Nurnberg). Axel is a member of the German Society of Market Access, the German Society of Health Economics, and the EU Market Access & Value Committee at ARM (Alliance for Regenerative Medicine). He published various articles on Benefit Assessment, Market Access, Healthcare-System Issues, Disease Awareness (i.e. in Rheumatoid Arthritis or Psoriasis), and on Claims-Data-Analysis with Real World Evidence.

Jolanda Koenders, NE

Director Patient Value & Access

Takeda

Jolanda Koenders (F), Director Patient Value & Access, and a.i. Director of Public Affairs in the Netherlands at Takeda. She has over 20 years’ experience in the pharmaceutical industry. With a background in clinical research and medical affairs, Jolanda has broad expertise in Evidence and Value Generation of innovative drugs. In addition, her personality and capabilities ensure long-term strategic relationships with internal- and external customers. Jolanda has a degree in Medical Biologie (MSc) and Health Technology Assessment. In the latter, she obtained practical experience in Pricing & Reimbursement, Market Access, and RWE in her role as Head Pricing & Market Access Novartis the Netherlands, previously delivering the reimbursement dossiers herself as Pricing &Access manager. In her current role, Jolanda manages the Patient Value & Access Managers (HTA and MoH) and Field Market Access managers (hospitals & health insurance companies contracting).

Dr. Carmen Montoto Otero, ES

Medical, Regulatory, and Quality Director

Takeda

Medical, Regulatory, and Quality Director at Takeda. MD, internal medicine specialist and Ph.D. and Epidemiology, Preventive Medicine, and Public Health. More than 20 years of experience in the health environment, with hospital clinical practice and Med Affairs, Research and epidemiology developed through consultancy, academy, and industry. In the pharma industry, she has developed her career in different positions in Medical Affairs and Scientific Area at GSK and BMS before arriving in Takeda. In Takeda Carmen built the medical department after the start-up of the company in Spain in 2009 with responsibilities during several years also in Portugal, managing the challenges of supporting an important platform of RWE and Evidence generation with an application of new technologies in this environment, among the key priority for Medical Department.

Jack Noble, UK

Analyst, Thought Leadership

IQVIA

Jack Noble is an analyst working in IQVIA’s European Thought leadership team based in London. His role is to perform data-driven research and analysis across a wide range of pharma market trends and developments with a particular interest in immunology and autoimmune diseases.

Prior experience in competitive intelligence contributes to his multi-faceted view of the pharma market and the multitude of factors that combine to elicit change. Jack holds a master’s degree in Biochemistry from the University of Oxford with a research focus on early-stage drug discovery and structural biology.

David Bower, US

Global Market Access and Pricing Lead – Dermatology

Sanofi Genzyme

As the Sanofi Genzyme Global Value & Access Lead for DUPIXENT in Dermatology indications, David oversees the global market access strategy development for DUPIXENT’s dermatology indications, primarily Atopic Dermatology (AD), as well as future dermatological indications in clinical development. Additionally, David co-leads various leadership brand functions representing Market Access in conjunction with Medical and Marketing teams and oversees critical governance processes to support payer discussions globally. In addition to supporting launch activities, David is deeply involved in overseeing Market Access strategy development and implementation for early future indications and complementary products in development.
 

Oliver Leatham, UK

Vice President, Head of Value & Access

Analytica Laser, a Certara company

Oliver Leatham is a global market access expert and head of Evidence and Access at Certara. His team includes evidence evaluation, HTA, pricing, health economic modeling, and payer engagement. Oliver spe­cialises in market access strategic planning and innovative contracting, with the ability to identify opportunities and negotiate the acceptance of accelerated product approvals. Previously, Oliver worked as the head of pricing and market access for PAREXEL and Head of Market Access for Astellas, combining client-side insights with broader consultancy experience. Oliver has extensive experience in product commercialization, service redesign, payer engagement, and payer marketing. He sat on the AWMSG Steering Committee (HTA body for Wales) and has won awards for partnering with the healthcare providers. His novel approaches to innovative contracting and service redesign, including integrated care pathways and virtual clinics, have been showcased and replicated across a number of health economies in Europe.

Axel Boehnke, DE

Director of Market Access EU North

PTC Therapeutics

Jolanda Koenders, NE

Director Patient Value & Access

Takeda

Dr. Carmen Montoto Otero, ES

Medical, Regulatory, and Quality Director

Takeda

Jack Noble, UK

Analyst, Thought Leadership

IQVIA

David Bower, US

Global Market Access and Pricing Lead – Dermatology

Sanofi Genzyme

Oliver Leatham, UK

Vice President, Head of Value & Access

Analytica Laser, a Certara company

What our
participants
are saying

“A great overview of major systems and the rationale behind pricing strategies. Well-structured program and enjoyable 2 days.”

1
2
3
4
5

SUMMIT

Attendee

“I will gladly join the next summit again. It was great to meet all the market access and pricing professionals from around the world. Great networking and free-flowing sharing of ideas, challenges.”

1
2
3
4
5

SUMMIT

Attendee

“Beyond my expectations! It was very insightful experience thanks to all the knowledgeable speakers. “

1
2
3
4
5

SUMMIT

Attendee